Last updated: December 12, 2022
Sponsor: Chong Kun Dang Pharmaceutical
Overall Status: Active - Recruiting
Phase
3
Condition
Hypercholesterolemia
Familial Hypercholesterolemia
Treatment
N/AClinical Study ID
NCT05657574
A52_08HCL2217
Ages > 19 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Adults ≥ 19 years of age
- Primary hypercholesterolemia
- Patients willing and able to discontinue ongoing lipid-lowering therapy according tothe opinion of the investigator
Exclusion
Exclusion Criteria:
- Secondary hypercholesterolemia
- Conditions / situations such as:
- Presence of any clinically significant uncontrolled endocrine/metabolic diseaseknown to influence lipids levels
- Severe renal impairment or active liver disease
- History of hypersensitivity or allergies to investigational drugs or drug of similarchemical classes.
- History of drug abuse or alcoholism within 24 weeks before screening
- Any surgical or medical condition which might significantly affect the absorption,distribution, metabolism, or excretion of investigational drugs
- Patients who have been taken with other investigational drugs within 8 weeks beforescreening
Study Design
Total Participants: 228
Study Start date:
November 24, 2022
Estimated Completion Date:
June 30, 2023
Study Description
Connect with a study center
Asan Medical Center
Seoul,
Korea, Republic ofActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.